close
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Sep:105:992-996.
doi: 10.1016/j.biopha.2018.06.076. Epub 2018 Jun 19.

Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome

Alberto Mazza  1 , Salvatore Lenti  2 , Laura Schiavon  3 , Ezio Di Giacomo  4 , Monica Tomasi  3 , Roberto Manunta  5 , Gioia Torin  6 , Danyelle M Townsend  7 , Domenico Rubello  8
Affiliations
Randomized Controlled Trial

Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome

Alberto Mazza et al. Biomed Pharmacother. 2018 Sep.

Abstract

Introduction: Metabolic syndrome (MetS) is a world-wide epidemic disease with an increased risk of morbidity and mortality. Treatment strategies of MetS include pharmacologic and non-pharmacologic interventions and in this respect a relevant role has been shown for nutraceutical compounds (NCs). The aim of this study was to investigate the efficacy and safety of NCs incorporated with diet and lifestyle management versus diet alone, in lowering blood pressure (BP) values and improving lipid and glucose profile, in a group of hypertensives and hyper-cholesterolemic patients with MetS.

Methods: 104 subjects with MetS (mean age 57.4 ± 8.8 years, 51% males) without history of cardio-vascular (CV) diseases were enrolled in the study. 52 subjects were treated with a once-daily oral formulation of a NCs containing red yeast rice and coenzyme Q10 added to their diet for 2 months and were compared with the 52 patients following a diet program. Differences in BP, serum total cholesterol (TC), low- and high-density-lipoprotein cholesterol (LDLC and HDLC), triglycerides (TG) and glucose values were compared by analysis of variance.

Results: A significant reduction of BP, TC, TG, LDLC and glucose levels was observed in both treatment groups. However, a greater reduction of systolic BP (-5.2 vs. -3.0 mmHg), diastolic BP (-4.9 vs. 2.9 mmHg), total cholesterol (-17.2%), LDLC (-21.8%), TG (-16.0%) and serum glucose (-3.4%) was observed in the treatment group relative to the control (p < 0.001 for all); HDLC remained unchanged (p = N.S.). Gender difference was not found in either group (p = N.S.).

Conclusions: In patients with MetS, NC supplementation was safe, well tolerated and effective in improving clinic BP, lipid and glucose profile.

Keywords: Blood pressure; Cholesterol; Diet; Lipids; Metabolic syndrome; Monacolin K.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

None.

Figures

Fig. 1.
Fig. 1.
Clinic systolic blood pressure (SBP) and diastolic blood pressure (DBP), serum total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDLC), low-density lipoproteins cholesterol (LDLC) and glucose changes from baseline to the follow-up in both groups. *p < 0.05 vs. baseline. ** < 0.001 vs. baseline;**T < 0.001 vs. Mediterranean Diet; MK 10: Monacolin K 10 mg; NS: non significant.
See this image and copyright information in PMC

Comment in

References

    1. Kaur J, A comprehensive review on metabolic syndrome, Cardiol. Res. Pract (2014) 21 943162. - PMC - PubMed
    1. El-Atat FA, Stas SN, McFarlane SI, Sowers J, Obesity and hypertension, Endocrinol. Metab. Clin. N. Am 32 (2003) 823–854. - PubMed
    1. European Food Safety Authority (EFSA), Scientific opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol concentrations (ID 1648, 1700) pursuant to article 13(1) of regulation (EC) no 1924/2006. EFSA panel on dietetic products, nutrition and allergies (NDA), EFSA J. 9 (7) (2011) 2304.
    1. Izzo R, de Simone G, Giudice R, Chinali M, Trimarco V, De Luca N, et al. , Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia, J. Hypertens 28 (2010) 1482–1487. - PubMed
    1. Trimarco B, Benvenuti C, Rozza F, Cimmino CS, Giudice R, Crispo S, Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet, Med. J. Nutr. Metab 4 (2011) 133–139. - PMC - PubMed

Publication types

MeSH terms